Guardion Health Sciences, Inc. (NASDAQ:GHSI) Sees Large Decrease in Short Interest

Guardion Health Sciences, Inc. (NASDAQ:GHSI) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 97,300 shares, a decline of 33.7% from the May 31st total of 146,800 shares. Based on an average daily trading volume, of 9,100 shares, the days-to-cover ratio is currently 10.7 days. Currently, 9.5% of the shares of the company are short sold.

Guardion Health Sciences Stock Performance

NASDAQ GHSI traded down $0.18 on Monday, reaching $9.85. The stock had a trading volume of 1,174 shares, compared to its average volume of 112,705. Guardion Health Sciences has a 12-month low of $5.01 and a 12-month high of $10.75. The business’s 50-day moving average price is $9.05 and its 200 day moving average price is $7.88. The stock has a market cap of $12.65 million, a P/E ratio of -2.50 and a beta of 0.83.

Guardion Health Sciences (NASDAQ:GHSI) last released its quarterly earnings results on Monday, May 13th. The company reported ($3.71) EPS for the quarter. Guardion Health Sciences had a negative return on equity of 77.29% and a negative net margin of 16.69%. The company had revenue of $3.00 million for the quarter.

Guardion Health Sciences Company Profile

Guardion Health Sciences, Inc, a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment.